A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
Future Oncology · 2023
DOI: 10.2217/fon-2022-1157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Ana Oaknin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GSK group of companies.
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study. WHAT WERE THE RESULTS?: The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects. WHAT DO THE RESULTS MEAN?: The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital.
- Campus, Barcelona, Spain.
- Department of Gynecologic Oncology, McGill University Health Centre Research Institute, Montreal, QC, Canada.
- Department of Medicine, BC Cancer, Vancouver, BC, Canada.
- Division of Gynecologic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
- Department of Gynecological Oncology, Women & Infants Hospital of Rhode Island, Providence, RI, USA.
Förderung
- GSK group of companies
Zitieren
APA
Oaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., Sabatier, R., O'Malley, D. M., Samouelian, V., Boni, V., Duska, L., Ghamande, S., Ghatage, P., Kristeleit, R., Leath, C., Dong, Y., Veneris, J., & Pothuri, B. (2023). A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology. https://doi.org/10.2217/fon-2022-1157
Vancouver
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology. 2023. doi:10.2217/fon-2022-1157
BibTeX
@article{Oaknin2023,
author = {Oaknin, Ana and Gilbert, Lucy and Tinker, Anna V and Brown, Jubilee and Mathews, Cara and Press, Joshua and Sabatier, Renaud and O'Malley, David M and Samouelian, Vanessa and Boni, Valentina and Duska, Linda and Ghamande, Sharad and Ghatage, Prafull and Kristeleit, Rebecca and Leath, Charles and Dong, Yuping and Veneris, Jennifer and Pothuri, Bhavana},
title = {A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2022-1157}
}
EUVIMED